Better overall lipid effects were seen in type 2 diabetes patients with coronary artery disease treated with metformin than those being treated with glipizide….
Results were analyzed in the SPREAD-DIMCAD study and 44 patients were evaluated, 23 on metformin and 21 on glipizide.
Using the SMART (scaled-to-maximum, aligned, and reduced trajectories) model strategy, researchers discovered metformin had a significant impact on lipid metabolism compared to glipizide treatment in type 2 diabetes patients with coronary artery disease.
The researchers found an association of three lipid metabolites, phosphatidylcholine, sphingomyelin (d18:0-24:1), and sphingomyelin (d18:1-20:1) with long term cardiovascular complications.
Dr. Zhang from Shanghai Jiao-Tong University School of Medicine, China, indicated metformin treatment would be preferred in type 2 diabetes patients who are at high risk of CV events over glipizide. She also believed detailed lipid profiles should be done in patients with type 2 diabetes to further look into the mechanism of an anti-diabetic drug and its effect on cardiovascular complications.
Further studies will be needed as the population in this study was extremely small.
- Researchers found metformin treatment has a higher lipid metabolism profile compared to glipizide treatment in T2DM.
- Three lipid metabolites are associated with cardiovascular complications long term.
- Metformin is preferred over glipizide for treatment for type 2 diabetes in patients with CVD.